Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study
Liebert A, Bicknell B, Laakso EL, Heller G, Jalilitabaei P, Tilley S, Mitrofanis J, Kiat H
BMC neurology · 82 citas
Etiquetas de revisión
Vínculos de autores con la industriaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Autores
- Al menos un autor declara un vínculo económico con la industria
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-07-02 · BMC Neurol · vol. 21 · número 1 · pág. 256
- Editorial
- BioMed Central
- Citado
- 112 citas · más que el 99% de estudios similares · 9.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 93 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Laser Applications in Dentistry and Medicine · Dermatologic Treatments and Research · Oral health in cancer treatment
- Palabras clave
- Medicine, Neurology, Randomized controlled trial, Neurosurgery, Placebo, Disease, Physical therapy, Clinical trial, Sequela, Neurochemistry, Physical medicine and rehabilitation, Internal medicine, Surgery, Alternative medicine, Psychiatry, Pathology
- MeSH
- humans, parkinson disease, prospective studies, low-level light therapy, covid-19, sars-cov-2
8 autores
- Ann D. Liebert🇦🇺 · autor de correspondenciaThe University of Sydney; Sydney Adventist Hospital
- Brian T. Bicknell
- E‐Liisa Laakso🇦🇺Griffith University; Mater Research
- Gillian Ziona Heller🇦🇺The University of Sydney; National Health and Medical Research Council; Macquarie University
- Parastoo Jalilitabaei🇦🇺The University of Sydney
- Sharon Tilley
- John Mitrofanis🇦🇺The University of Sydney
- Hosen Kiat🇦🇺Victor Chang Cardiac Research Institute; UNSW Sydney; Macquarie University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons.
Objective
To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT).
Methods
Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%.
Results
Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed.
Conclusions
PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted.
Trial registration
Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p , registered on 12/01/2018.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.